Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midodrine, Octreotide and Albumin in Hepatorenal Syndrome
NCT01587222Phase 2Withdrawn
- Start
- Jul 2016
- Primary completion
- Jul 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of albumin (human), midodrine, Octreotide long-acting injection in hepatorenal syndrome (HRS). Planned start Jul 2016; status: withdrawn.
02
Drugs
albumin (human)midodrineOctreotide long-acting injection
03
Conditions
hepatorenal syndrome (HRS)
Beyond the preview
Go deeper on NCT01587222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01587222.